Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
MELBOURNE, Australia and INDIANAPOLIS, May 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been...
NetDragon Participates in Digital China Summit for the 8th Consecutive Year, Pioneering AI-Driven Innovation in Gaming and Education
HONG KONG, May 7, 2025 /PRNewswire/ -- NetDragon Websoft Holdings Limited ("NetDragon" or the "Company"; Hong Kong Stock Code: 0777), a global leader in building internet communities, is pleased to announce its participation in the 8th Digital China...
Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity
HONG KONG, May 6, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces oral and poster presentations on preliminary studies of ASC47, an adipose-targeted, muscle-preserving weight loss drug candidate for obesity, will be...
Gamma Communications Recognized with Frost & Sullivan's 2024 European UCaaS Competitive Strategy Leadership Award
The company has shown exceptional strategy execution, innovation, and customer-centric growth in a rapidly evolving market. SAN ANTONIO, Texas, May 6, 2025 /PRNewswire/ -- Frost & Sullivan is proud to present Gamma Communications with the 2024...
IND Application for NTS071, Nutshell Therapeutics' p53 Y220C Allosteric Reactivator, Received US FDA clearance
SHANGHAI, May 4, 2025 /PRNewswire/ -- On April 23, 2025, Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate P hase 1 clinical trial in the United States for its NTS071, a novel small molecule allosteric...
A Pivotal Phase II/III Clinical Study of Anti-HER2 Bispecific Antibody KN026 Have Met the Primary Endpoint of PFS at Interim Analysis
SUZHOU, China, May 1, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that a phase II/III clinical trial of anti-HER2 bispecific antibody KN026...
Amorepacific Research Confirms Potential of Microalgal-Derived PDRNs in Skin Regeneration and Wound Healing
New findings suggest 'BluePDRN™' offers a sustainable, scalable alternative to traditional animal-derived PDRNs SEOUL, South Korea, April 29, 2025 /PRNewswire/ -- Amorepacific revealed research findings confirming the skin-regenerative effects of...
Antaisolar Shines at Green Energy Expo 2025 in Korea with BIPV and Versatile Mounting Solutions
DAEGU, South Korea, April 28, 2025 /PRNewswire/ -- From April 23 to 25, 2025, Antaisolar made a strong appearance at Green Energy Expo 2025 in Daegu, South Korea, showcasing its latest BIPV systems, rooftop mounting structures, and ground-mounted...
Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA
- ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of 2 mg, 10 mg, 20 mg , and 40 mg doses. - ASC30 oral once-daily tablet also...
SKYWORTH Unveils Revolutionary OmniView Matte Screen, Pushing MiniLED Displays to OLED-Level Performance
SHENZHEN, China, April 22, 2025 /PRNewswire/ -- From April 15 to 19, 2025, SKYWORTH once again took center stage at the 137th China Import and Export Fair (Canton Fair), showcasing its latest breakthroughs in consumer electronics and setting new...